Biomatter, a Vilnius-based synthetic biology company that creates new proteins for health and sustainable manufacturing applications, has secured €6.5 million in a seed funding round led by Inventure and UVC Partners. The round was also joined by existing investors, Practica Capital and Metaplanet, as well as business angels and industry experts.

About Biomatter

  • The company, founded by Laurynas Karpus, develops the Intelligent Architecture™ platform that helps people overcome the limitations of current engineering approaches to unlock completely new horizons for protein design and development.
  • In 2021, the Biomatter team published a study demonstrating that their generative AI tool can analyse large amounts of enzyme data and design new enzymes, marking a significant breakthrough in the field. Generative AI and physics enable precise, sequence-based design of proteins, enabling large-scale function and property improvements.

“The application of AI in protein design will be transformational, addressing major current design limitations. Early results from projects with global companies show that Biomatter’s technology is dramatically accelerating innovation in this transformative field, reshaping the implementation of enzymes in incumbent and new structures. The team is rapidly expanding its platform to meet high customer demand,” Kevin Lösch, Investment Manager at Inventure, says about the startup.

Investment details

  • The early-stage venture capital firm Inventure is one of the lead investors this round. The firm is skilled at helping creators from the Baltic and Nordic regions advance. With headquarters in Helsinki and Stockholm, its team has been in venture with over 90 firms since 2005, spanning from consumer internet brands to deep tech startups. Inventure, which  manages €377 million in assets, specialises in early-stage investments in the Nordic and Baltic regions, usually with ticket sizes ranging from €500,000 to up to €5,000,000. 
  • UVC Partners, a Munich-based venture capital firm, is the other lead investor. The firm invests in European B2B digital start-ups from pre-seed to series A. With assets of €400 million, they invest between €500,000 and €10 million, with a portfolio of technologies in mobility, hard- and software development, climate tech, deep tech, and mobility.
  • The existing investors Practica Capital and Metaplanet, as well as unnamed business angels and industry experts, also joined the financing.

Biomatter's new investment round will allow them to expand their platform's unique capabilities and develop innovative enzymes, bolstering their rapidly growing global customer base.